racemetirosine has been researched along with Schizophrenia in 9 studies
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies demonstrated increased striatal dopamine (DA) release after amphetamine challenge and increased striatal baseline occupancy of D2 receptors in patients with schizophrenia compared with control subjects." | 3.75 | Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. ( Abi-Dargham, A; Kegeles, LS; Laruelle, M; Slifstein, M; van de Giessen, E, 2009) |
| "The antipsychotic effect of alpha-methyltyrosine (alpha-MT) in combination with thioridazine was investigated by means of rating scales for "social behaviour" and "mental symptoms"." | 1.27 | Antipsychotic treatment with alpha-methyltyrosine in combination with thioridazine: prolactin response and interaction with dopaminergic precursor pools. ( Carlsson, A; Larsson, M; Ohman, R; Wålinder, J; Wallin, L, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| da Silva Alves, F | 1 |
| Bakker, G | 1 |
| Schmitz, N | 1 |
| Abeling, N | 1 |
| Hasler, G | 1 |
| van der Meer, J | 1 |
| Nederveen, A | 1 |
| de Haan, L | 1 |
| Linszen, D | 1 |
| van Amelsvoort, T | 1 |
| Abi-Dargham, A | 4 |
| van de Giessen, E | 1 |
| Slifstein, M | 2 |
| Kegeles, LS | 3 |
| Laruelle, M | 4 |
| Frankle, WG | 1 |
| Gil, R | 2 |
| Cooper, TB | 3 |
| Hwang, DR | 2 |
| Huang, Y | 1 |
| Haber, SN | 1 |
| Guo, N | 1 |
| Lo, ES | 1 |
| Huang, YY | 1 |
| Voruganti, LN | 1 |
| Awad, AG | 2 |
| Larsson, M | 1 |
| Ohman, R | 1 |
| Wallin, L | 1 |
| Wålinder, J | 1 |
| Carlsson, A | 1 |
| Wolkin, A | 1 |
| Duncan, E | 1 |
| Sanfilipo, M | 1 |
| Wieland, S | 1 |
| Rotrosen, J | 1 |
| Rodenhiser, J | 1 |
| Printz, D | 1 |
| Zea-Ponce, Y | 1 |
| Weiss, R | 1 |
| Mann, JJ | 1 |
| Van Heertum, RL | 1 |
| Gorman, JM | 1 |
| Voruganti, L | 1 |
| Slomka, P | 1 |
| Zabel, P | 1 |
| Costa, G | 1 |
| So, A | 1 |
| Mattar, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Cannabinoid CB1 Receptors in Schizophrenia[NCT01063335] | 1 participants (Actual) | Observational | 2010-02-01 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for racemetirosine and Schizophrenia
| Article | Year |
|---|---|
Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study.
Topics: Adult; alpha-Methyltyrosine; Anticipation, Psychological; Brain; Brain Mapping; Dopamine; Double-Bli | 2013 |
Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging.
Topics: Adult; Affect; alpha-Methyltyrosine; Benzamides; Dopamine; Enzyme Inhibitors; Female; Humans; Image | 2001 |
7 other studies available for racemetirosine and Schizophrenia
| Article | Year |
|---|---|
Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects.
Topics: Adult; alpha-Methyltyrosine; Amphetamine; Benzamides; Dopamine; Dopamine Uptake Inhibitors; Enzyme I | 2009 |
Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.
Topics: Adult; alpha-Methyltyrosine; Brain Mapping; Carbon Radioisotopes; Case-Control Studies; Caudate Nucl | 2010 |
Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia.
Topics: Adrenergic Uptake Inhibitors; alpha-Methyltyrosine; Animals; Benzazepines; Benzofurans; Binding Site | 2003 |
Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study.
Topics: Adult; alpha-Methyltyrosine; Catecholamines; Corpus Striatum; Dopamine; Dopamine Antagonists; Enzyme | 2006 |
Antipsychotic treatment with alpha-methyltyrosine in combination with thioridazine: prolactin response and interaction with dopaminergic precursor pools.
Topics: Aged; alpha-Methyltyrosine; Antipsychotic Agents; Dopamine; Drug Therapy, Combination; Humans; Male; | 1984 |
Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.
Topics: Adult; alpha-Methyltyrosine; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine; Drug Resistance | 1994 |
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.
Topics: Adult; alpha-Methyltyrosine; Antipsychotic Agents; Chronic Disease; Corpus Striatum; Dopamine; Femal | 2000 |